2 0 2 0 b u s i n e s s r e s u l t s o c t o b e r 2 7
TRANSCRIPT
2 0 2 0 B U S I N E S S R E S U L T S O C T O B E R 2 7 , 2 0 2 0
Not for promotional use 2
Not for promotional use 3
Not for promotional use 4
•
•
•
•
•
•
•
•
•
•
•
•
Not for promotional use 5
•
•
•
•
•
•
•
•
•
•
•
•
•
•
Not for promotional use 6
•
•
•
•
•
•
•
•
Not for promotional use 7
Not for promotional use 8
Not for promotional use 9
Not for promotional use 10
o
o
o o
o
o
Not for promotional use 11
Not for promotional use 12
Not for promotional use 13
Not for promotional use 14
Not for promotional use 15
▪
▪
▪
▪
▪
▪
▪
▪
▪
▪
▪
▪
▪
▪
▪
▪
▪
▪
AUTOMATED INSULIN DELIVERY SYS Diabetes
BASAL INSULIN-FCDiabetes
OXYNTOMODULINDiabetes
AUR A KINASE INHIBITOR Cancer
MIRIKIZUMABCrohn’s Disease
BARICITINIB Systemic Lupus Erythematosus
MEVIDALEN (D1 PAM)Dementia
ZAGOTENEMAB (TAU MAB) Alzheimer’s
TIRZEPATIDEDiabetes
DONANEMAB (N3PG Ab MAB) Alzheimer’s
BARICITINIBAtopic Dermatitis
EMPAGLIFLOZIN*Heart Failure pEF
TANEZUMAB*Cancer Pain
ABEMACICLIBAdjuvant Breast Cancer
MIRIKIZUMABPsoriasis
TANEZUMAB*Osteoarthritis Pain
SOLANEZUMABPreclinical AD
MIRIKIZUMABUlcerative Colitis
BARICITINIBAlopecia Areata
NME
NILEX
*
MOVEMENT SINCEJuly 28, 2020
ACHIEVED MILESTONE
REMOVALCommercial
Collaboration
OLARATUMABPancreatic Cancer
BTLA MAB AGONISTImmunology
ABEMACICLIBProstate Cancer
PD-1 MAB AGONISTImmunology
CD200R MAB AGONISTImmunology
PACAP38 MABPain
BTK INHIBITOR (LOXO-305) Cancer
EMPAGLIFLOZIN*Chronic Kidney Disease
O-GLCNACASE INHAlzheimer’s
GGG TRI-AGONISTDiabetes
CDK7 INHIBITORCancer
CONNECTED CARE PREFILLED INSULIN PEN Diabetes
GLP-1R NPADiabetes
TRPA1 ANTAGONIST Pain
SSTR4 AGONISTPain
D1 PAM IIDementia
ANGPTL3/8 MABCVD
SERDCancer
TIRZEPATIDEObesity
LEBRIKIZUMABAtopic Dermatitis
SELPERCATINIB1L Med Thyroid Cancer
SELPERCATINIB1L NSCLC
TIRZEPATIDENASH
GIP/GLP COAGONIST PEPTIDE Diabetes
N3PG Ab MABAlzheimer’s
BARICITINIB^COVID-19
BAMLANIVIMAB^(LY-CoV555) COVID-19
ETESEVIMAB+
(LY-CoV016) COVID-19
TIRZEPATIDECV Outcomes
EPIREG/TGFaMABChronic Pain
NRG4 AGONISTHeart Failure
EMPAGLIFLOZIN*Heart Failure rEF
KHK INHIBITORNASH / Diabetes
IL-2 CONJUGATEImmunology
CXCR1/2L MABImmunology
ANGIOPOIETIN 2MAB COVID-19
LP(a) INHIBITORCVD
DULAGLUTIDE3.0 / 4.5 mg
CD73 INHIBITORCancer
TAU MORPHOMERAlzheimer’s
GDF 15 AGONISTDiabetes
^ Under Regulatory Review for
Emergency Use Authorization
+ In combination with bamlanivimab, potentially
registrational study
IDH1 INHIBITOR Cancer
Not for promotional use
Not for promotional use
17
✓
✓
✓
✓ ✓
✓ ✓
✓ ✓
✓
✓
✓
✓
✓-
✓-
✓ ✓✓
✓
New since last update
✓
✓
✓
✓
✓ ✓
✓
✓
✓
✓ ✓
✓
✓
✓
✓
✓
✓
✓
✓ `
✓
✓
✓
Not for promotional use 18
▪
▪
▪
▪
▪
•
•
•
•
Not for promotional use 20
Not for promotional use 21
Not for promotional use 22
Not for promotional use 23
Not for promotional use 24
Not for promotional use 25
•
•
•
•
Not for promotional use 26
•
•
•
•
•
•
•
•
•
Not for promotional use 27
Not for promotional use 28
Not for promotional use 29
Not for promotional use 30
Not for promotional use 31
Not for promotional use 32
Not for promotional use 33
Not for promotional use 34
•
•
•
Not for promotional use 35
Not for promotional use 36
•
•
•
Not for promotional use 37
Not for promotional use 38
Not for promotional use 39
Not for promotional use 40
<≥
Not for promotional use 41
>
>
>
Not for promotional use 42
Not for promotional use 43
Not for promotional use 44
<
<
Not for promotional use 45
Not for promotional use 46
Not for promotional use 47
Not for promotional use 48
Not for promotional use 49
Not for promotional use 50
Not for promotional use 51
Not for promotional use 52
Not for promotional use 53
Not for promotional use 54
>
Not for promotional use 55
Not for promotional use 56
β
β
Not for promotional use 57
β
Not for promotional use 58
Not for promotional use 59
